CA2214029A1 - Single-vial formulations of dna/lipid complexes - Google Patents

Single-vial formulations of dna/lipid complexes Download PDF

Info

Publication number
CA2214029A1
CA2214029A1 CA002214029A CA2214029A CA2214029A1 CA 2214029 A1 CA2214029 A1 CA 2214029A1 CA 002214029 A CA002214029 A CA 002214029A CA 2214029 A CA2214029 A CA 2214029A CA 2214029 A1 CA2214029 A1 CA 2214029A1
Authority
CA
Canada
Prior art keywords
solution
cationic lipid
plasmid dna
lipid
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002214029A
Other languages
English (en)
French (fr)
Inventor
Magda Marquet
Diana L. Burman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresh Tracks Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2214029A1 publication Critical patent/CA2214029A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
CA002214029A 1995-04-25 1996-04-11 Single-vial formulations of dna/lipid complexes Abandoned CA2214029A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42846395A 1995-04-25 1995-04-25
US08/428,463 1995-04-25

Publications (1)

Publication Number Publication Date
CA2214029A1 true CA2214029A1 (en) 1996-10-31

Family

ID=23699001

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002214029A Abandoned CA2214029A1 (en) 1995-04-25 1996-04-11 Single-vial formulations of dna/lipid complexes

Country Status (4)

Country Link
EP (1) EP0826063A1 (ja)
JP (1) JPH11504631A (ja)
CA (1) CA2214029A1 (ja)
WO (1) WO1996034109A1 (ja)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770715A (en) * 1995-03-22 1998-06-23 Toagosei Co., Ltd. Hammerhead-like nucleic acid analogues and their synthesis
DE69725877T2 (de) 1996-08-26 2004-07-22 Transgene S.A. Kationische lipid-nukleinsäure komplexe
CA2270396C (en) * 1996-11-04 2008-03-11 Qiagen Gmbh Cationic reagents for transfection
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US6534483B1 (en) 1998-08-14 2003-03-18 Valentis, Inc. Protected one-vial formulation for nucleic acid molecules, methods of making the same by in-line mixing, and related products and methods
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
KR100768114B1 (ko) * 1999-06-10 2007-10-17 메리알 애완 동물 및 스포츠용 동물을 위한 ｄｎａ 백신
FR2794648B1 (fr) * 1999-06-10 2003-03-07 Merial Sas Vaccins adn pour animaux de compagnie et de sport
DE19944262A1 (de) * 1999-09-15 2001-03-29 Cardiogene Gentherapeutische S Pharmazeutische Zusammensetzung in Form eines Nukleinsäure-Lipid-Komplexes, ihre Herstellung und Verwendung in der Gentherapie
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
FR2810888B1 (fr) 2000-06-29 2004-07-30 Merial Sas Vaccin contre la fievre aphteuse
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
AU2003275127A1 (en) 2002-09-19 2004-04-08 Merial Limited P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
WO2004039958A2 (en) 2002-10-29 2004-05-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lutzomyia longipalpis polypeptides and methods of use
US7354593B2 (en) 2002-12-09 2008-04-08 Merial Limited Coccidial vaccine and methods of making and using same
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
WO2006115843A2 (en) 2005-04-25 2006-11-02 Merial Limited Nipah virus vaccines
CA2619174C (en) 2005-08-15 2016-12-20 Vaxin, Inc. Immunization of avians by administration of non-replicating vectored vaccines
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
EP1951751B1 (en) 2005-11-14 2017-11-01 Merial, Inc. Gene therapy for renal failure
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7455844B2 (en) 2006-03-29 2008-11-25 Merial Limited Vaccine against streptococci
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
JP5403324B2 (ja) 2006-11-24 2014-01-29 学校法人早稲田大学 タンパク質又は遺伝子導入用試薬
CA2684923C (en) 2007-05-02 2015-01-06 Merial Limited Dna plasmids having improved expression and stability
US20090111099A1 (en) * 2007-10-27 2009-04-30 Yongsheng Ma Promoter Detection and Analysis
EP2283035B1 (en) 2008-05-08 2015-07-29 Merial Limited Leishmania vaccine using sand fly salivary immunogen
CN102271704A (zh) 2008-11-28 2011-12-07 梅里亚有限公司 重组禽流感疫苗及其用途
EP2414386B1 (en) 2009-04-03 2016-01-27 Merial Limited Newcastle disease virus vectored avian vaccines
SI2432884T1 (sl) 2009-05-22 2016-11-30 Merial, Inc. Plazmid brez antibiotika
CA2785653C (en) 2009-12-28 2018-05-01 Merial Limited Recombinant ndv antigen and uses thereof
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
BR112012023852B1 (pt) 2010-03-12 2020-11-10 Biolex Therapeutics vacinas recombinantes do vírus da língua azul e usos das mesmas
BR112013007486B1 (pt) 2010-08-31 2020-01-28 Merial Ltd composição, vetor recombinante de ndv e uso da referida composição
AU2012245395A1 (en) 2011-04-20 2013-11-14 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
ES2764079T3 (es) 2011-05-27 2020-06-02 Boehringer Ingelheim Animal Health Usa Inc Vacunas genéticas contra el virus Hendra y el virus Nipah
CA2837375C (en) 2011-06-01 2019-07-16 Merial Limited Needle-free administration of prrsv vaccines
LT2734230T (lt) 2011-07-20 2019-03-25 Merial Limited Rekombinantinė kačių leikemijos viruso vakcina, turinti optimizuotą kačių leukemijos viruso apvalkalo geną
JP6041361B2 (ja) 2011-08-12 2016-12-07 メリアル インコーポレイテッド 生物学的製品、特にはワクチンの真空保存
JP6149240B2 (ja) 2012-02-14 2017-06-21 メリアル インコーポレイテッド ロタウイルスサブユニットワクチン並びにその製造及び使用方法
NZ628270A (en) 2012-02-14 2016-09-30 Merial Inc Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
NZ700470A (en) 2012-03-20 2016-04-29 Merial Inc Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
ES2664069T3 (es) 2012-06-13 2018-04-18 Merial, Inc. Vacunas contra BTV y AHSV de genoma reordenado
EP4091629A1 (en) 2013-09-25 2022-11-23 Zoetis Services LLC Pcv2b divergent vaccine composition and methods of use
CA2948845C (en) 2014-05-14 2022-05-31 Merial, Inc. Methods for freeze-drying and rehydrating biologics
AU2016282772B2 (en) 2015-06-23 2019-09-05 Boehringer Ingelheim Animal Health USA Inc. PRRSV minor protein-containing recombinant viral vectors and methods of making and use thereof
US10617752B2 (en) 2015-06-26 2020-04-14 Boehringer Ingelheim Animal Health USA Inc. Inactivated canine influenza vaccines and methods of making and uses thereof
AU2016332037B2 (en) 2015-09-29 2019-06-27 Boehringer Ingelheim Animal Health USA Inc. Canine parvovirus (CPV) virus-like particle (VLP) vaccines and uses thereof
EP3380119B1 (en) 2015-11-23 2021-08-25 Boehringer Ingelheim Animal Health USA Inc. Fmdv and e2 fusion proteins and uses thereof
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
WO2019207060A1 (en) * 2018-04-25 2019-10-31 Ethris Gmbh Lipid-based formulations for the delivery of rna
JP7271026B1 (ja) 2021-12-28 2023-05-11 株式会社Hyperion Drug Discovery 遺伝子導入細胞の免疫応答を回避させるための剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990003808A1 (en) * 1988-10-07 1990-04-19 The Liposome Company, Inc. Heat treating liposomes
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE4131562A1 (de) * 1991-09-18 1993-03-25 Medac Klinische Spezialpraep Arzneistofftraeger aus festen lipidteilchen-feste lipidnanosphaeren (sln)

Also Published As

Publication number Publication date
WO1996034109A1 (en) 1996-10-31
JPH11504631A (ja) 1999-04-27
EP0826063A1 (en) 1998-03-04

Similar Documents

Publication Publication Date Title
CA2214029A1 (en) Single-vial formulations of dna/lipid complexes
DE69725878T2 (de) Zusammensetzungen zur polynukleotidabgabe
US8771728B2 (en) Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) Stable lipid-comprising drug delivery complexes and methods for their production
US7070807B2 (en) Branched histidine copolymers and methods for using same
EP0795015B1 (en) Plasmids suitable for il-2 expression
US7163695B2 (en) Histidine copolymer and methods for using same
DE69434447T2 (de) Für die gentherapie verwendbare plasmide
US20030203865A1 (en) Lipid-comprising drug delivery complexes and methods for their production
JP2001508815A (ja) カチオン性ポリマー／脂質核酸送達ビヒクル
CA2340416C (en) Co-lyophilized complex of a nucleic acid vector and a formulating agent
JP2001526181A (ja) 遺伝子輸送体であるグラフト共重合体
EP0931156A2 (en) Gene expression and delivery systems and uses
JPWO2005054486A1 (ja) 遺伝子導入試薬調製法
JP2001502736A (ja) キトサン含有組成物
JP2003531181A (ja) 核酸を細胞に投与するための粒状複合体
WO2024023361A1 (en) Nanoparticles and peptides for the delivery of cargos to chondrocytes
AU2003238331B2 (en) Delivery system for pharmaceutical agents
AU8724001A (en) Gene expression and delivery systems and uses

Legal Events

Date Code Title Description
FZDE Dead